USA Archives

News and Trends 24 Aug 2022

Oncolyze seeking investment for AML clinical trials

After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […]

August 24, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Amgen announces top-line results from biosimilar phase 3 study

Amgen has announced positive top-line results from its DAHLIA study. This was a randomized, double-blind, active-controlled, two-period crossover phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Amgen said the study met its primary endpoints, demonstrating […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

Cytimmune Sciences nanoparticles red recognizing entering and accumulating in cancer cells

News and Trends 23 Aug 2022

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Gate Neurosciences emerges from stealth to tackle CNS diseases

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

Alume Biosciences announces first patient dosed with ALM 488

News and Trends 23 Aug 2022

Alume Biosciences progressing with fluorescence study in patients undergoing head and neck surgery

Alume Biosciences, Inc. says the first patient has been dosed in a phase 3 pivotal study of ALM-488, a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery. “The successful initiation of this phase 3 pivotal study is another major milestone for Alume Biosciences. It marks the final phase of clinical […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Ocelot Bio receives FDA Orphan Drug Designation for lead candidate for treatment of hepatorenal syndrome

Ocelot Bio, Inc., a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead candidate OCE-205 for the treatment of hepatorenal syndrome. Ocelot Bio is currently enrolling patients in a phase 2 clinical trial of OCE-205 in hepatorenal syndrome with acute kidney injury (HRS-AKI), […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine

The National Institute of Allergy and Infectious Disease (NIAID) has awarded a $6.9 million grant to researchers at the Institute for Bioscience and Biotechnology Research (IBBR) to design a vaccine to combat the virus that causes hepatitis C. Hepatitis C is an illness that affects an estimated 71 million people worldwide. Hepatitis C Virus (HCV) […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Aug 2022

Drug to treat rare kidney disease to be reviewed by EMA

The European Medicines Agency (EMA) has agreed to review a conditional marketing authorization (CMA) application for a drug to treat a rare kidney disorder. The news was announced today (August 21) by CSL Vifor and Travere Therapeutics Inc, and, if approved, the companies say sparsentan will address a significant unmet need in treating IgA nephropathy […]

August 22, 2022 - 3 minutesmins - By Liza Laws

Interview 22 Aug 2022

Hiring practices are shifting as biotech goes digital

Cloud computing is becoming increasingly prevalent as demand for global collaborations grows. Sajith Wickramasekara, founder and CEO of the cloud lab software provider Benchling, explains how this shift is affecting the labor market in the biotech industry. The biotech industry is becoming increasingly enmeshed with the world of digital technology, as companies search for ways […]

August 22, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 22 Aug 2022

EpiVario looks to biotech for PTSD treatment

Emerging U.S. biotech company EpiVario, Inc. has highlighted preclinical research findings that could lead to a treatment approach for post-traumatic stress disorder (PTSD). Published in Proceedings of the National Academy of Sciences (PNAS), and co-authored by the academic co-founders of EpiVario, the study demonstrates that fear memories can be controlled through the enzyme acetyl-CoA synthetase […]

August 22, 2022 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Oncolyze seeking investment for AML clinical trials

Amgen announces top-line results from biosimilar phase 3 study

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

Gate Neurosciences emerges from stealth to tackle CNS diseases

Alume Biosciences progressing with fluorescence study in patients undergoing head and neck surgery

Ocelot Bio receives FDA Orphan Drug Designation for lead candidate for treatment of hepatorenal syndrome

Institute for Bioscience and Biotechnology Research awarded $6.9M to work on hepatitis C vaccine

Drug to treat rare kidney disease to be reviewed by EMA

Hiring practices are shifting as biotech goes digital

EpiVario looks to biotech for PTSD treatment

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!